Clinical Trial Update: Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial comparing PEG-rhG-CSF as secondary prophylaxis versus therapeutic administration in ovarian cancer patients undergoing adjuvant chemotherapy; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• PEG-rhG-CSF (pegylated recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: Shandong University | Conditions: Adjuvant Chemotherapy, Ovarian Neoplasms | Phase 4 | Status: TERMINATED